Malignant neoplasm of breast – Page 2

AstraZeneca and SOPHiA GENETICS Expand AI-Powered Cancer Testing Collaboration

3 months ago talkbio0Tagged Artificial Intelligence, AstraZeneca, cancer testing, High-Throughput Nucleotide Sequencing, Malignant neoplasm of breast, Malignant neoplasm of prostate, PIK3CA/AKT1/PTEN pathway, Precision Medicine, real-world evidence, SOPHiA GENETICS

AstraZeneca; SOPHiA GENETICS; AI; cancer testing; breast cancer; prostate cancer; next generation sequencing (NGS); PIK3CA/AKT1/PTEN pathway; real-world evidence; precision medicine

Pfizer and Arvinas Abandon Commercialization of PROTAC Inhibitor, Triggering Layoffs and Pipeline Refocus

3 months ago talkbio0Tagged Arvinas, CDK inhibitors, layoffs, Malignant neoplasm of breast, Neoplasms, Pfizer, Protac, United States Food and Drug Administration, Vepdegestrant

Pfizer; Arvinas; PROTAC; vepdegestrant; layoffs; out-licensing; FDA; breast cancer; oncology; CDK inhibitors

Eli Lilly Highlights Verzenio’s Survival Benefit Amid Novartis Competition in Early Breast Cancer

4 months ago talkbio0Tagged Adjuvant Therapy, Clinical Trials, eli lilly, HER2-, HR+, Kisqali, Malignant neoplasm of breast, Novartis, Overall Survival, Verzenio

Verzenio; Eli Lilly; Novartis; Kisqali; early breast cancer; overall survival; adjuvant therapy; HR+; HER2-; clinical trial

AstraZeneca Expands AI Collaboration with SOPHiA GENETICS for Breast Cancer Research

5 months ago talkbio0Tagged AI Factories, AstraZeneca, Clinical Data, Genomics, Malignant neoplasm of breast, predictive models, real-world evidence, SOPHiA GENETICS

AstraZeneca; SOPHiA GENETICS; AI Factories; breast cancer; predictive models; real-world evidence; genomics; clinical data

NUCLIDIUM Sees Copper Isotopes as Future of Radiopharmaceuticals, Raises CHF 79M to Advance Clinical Development

6 months ago talkbio0Tagged cancer diagnostics, cancer therapeutics, copper isotopes, Malignant neoplasm of breast, Metastatic Prostate Carcinoma, Neoplasms, Neuroendocrine Tumors, NUCLIDIUM, NuriPro, Radiopharmaceuticals, Series B financing, Theranostics, TraceNET

NUCLIDIUM; copper isotopes; radiopharmaceuticals; Series B financing; Cu-NuriPro; NuriPro; TraceNET; oncology; theranostics; metastatic prostate cancer; neuroendocrine tumors; breast cancer; cancer diagnostics; cancer therapeutics

Kymera Snags Gilead as New Partner; Sanofi Opts for Next-Gen IRAK4 Degrader

6 months ago talkbio0Tagged biotech collaborations, CDK2 protein, human, Degrader, Gilead Sciences, IRAK4 gene, Kymera, Malignant neoplasm of breast, Molecular Glue Degrader, oncology partnership, sanofi, Solid Neoplasm

Kymera Therapeutics; Gilead Sciences; Sanofi; molecular glue degrader; CDK2; solid tumors; breast cancer; oncology partnership; IRAK4 degrader; biotech collaborations

Inside ASCO 2025: Big Data Drops and a Towering Campaign – Key News Highlights

7 months ago talkbio0Tagged 2025, Artificial Intelligence, ASCO, Big Data, campaigns, Cancer Research, Clinical Oncology, erbB-2 Receptor, Malignant neoplasm of breast, Malignant neoplasm of lung

ASCO 2025; cancer research; big data; campaigns; clinical oncology; artificial intelligence; HER2; lung cancer; breast cancer; therapeutic vaccines

RadNet Acquires See-Mode to Expand AI Ultrasound for Breast and Thyroid Cancer Diagnostics

7 months ago talkbio0Tagged Acquisition, AI ultrasound, Approved, DeepHealth, Diagnostic Imaging, Malignant neoplasm of breast, Malignant neoplasm of thyroid, RadNet, See-Mode, Technology, United States Food and Drug Administration, workflow efficiency

RadNet; See-Mode Technologies; AI ultrasound; breast cancer; thyroid cancer; DeepHealth; diagnostic imaging; FDA approval; workflow efficiency; acquisition

AstraZeneca Details Its Oral SERD ‘Switching’ Regimen Amid Feasibility Questions

7 months ago talkbio0Tagged AstraZeneca, camizestrant, CDK4/6 inhibitor, Disease Progression, ESR1 gene, Malignant neoplasm of breast, Mutation, Oral SERD, SERENA-6 trial, treatment resistance

AstraZeneca; oral SERD; camizestrant; breast cancer; ESR1 mutation; SERENA-6 trial; CDK4/6 inhibitor; disease progression; ASCO 2025; treatment resistance

Mersana makes Emi-Le the one, laying off 55% of staff to narrow focus to B7-H4 ADC

8 months ago talkbio0Tagged 55%, Antibody-Drug Conjugates, Emi-Le, emiltatug ledadotin, Malignant neoplasm of breast, Mersana, VTCN1 gene

Emi-Le, Mersana, VTCN1 gene, Antibody-Drug Conjugates, emiltatug ledadotin, Malignant neoplasm of breast, 55%